Related Experiment Video
Updated: Jun 7, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Combination Effect of Radiotherapy and Targeted Therapy with NK Cell-Based Immunotherapy in head and Neck Squamous
Woo-Chang Son1, Hong-Rae Lee1, Eun-Kyoung Koh1
1Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, South Korea.
Background:
Head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and current treatments are limited by high toxicity and low survival rates, highlighting the need for new therapeutic approaches. Natural killer (NK) cells can identify and eliminate cancer cells without prior antigen exposure. Radiotherapy directly targets tumors and increases activating ligands on tumor cells, promoting NK cell interactions. Cetuximab, an EGFR-targeting antibody, enhances NK cell cytotoxicity. Additionally, anti-PD-1 antibodies may further boost NK cell function by blocking inhibitory signals. The study aimed to enhance HNSCC treatment efficacy by combining radiotherapy and targeted therapy with expanded NK cells.
Methods:
NK cells were isolated, activated, and expanded from healthy donors. The FaDu and SCC-47 cell lines were inoculated into NOD/SCID mice. The mice were treated with PD-1 inhibitors, cetuximab, and radiation, followed by intravenous injection of NK cells.
Results:
Radiation increased ligands that regulate NK cell sensitivity. The combination of cetuximab, radiotherapy, and expanded NK cells significantly suppressed cancer progression and improved survival rates. However, adding anti-PD-1 antibodies did not further enhance outcomes.
Conclusion:
This study suggests that a multimodal approach combining cetuximab, radiotherapy, and NK cells can significantly improve HNSCC therapy efficacy, offering a novel and promising treatment strategy.
Insights
Combining cetuximab, radiotherapy, and natural killer (NK) cells shows promise for treating head and neck squamous cell carcinoma (HNSCC). This approach significantly improved survival and suppressed cancer progression in preclinical models.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge with limited treatment options and poor prognoses.
- Natural killer (NK) cells offer a promising avenue for cancer immunotherapy due to their ability to target tumor cells.
- Existing treatments for HNSCC often involve high toxicity and suboptimal survival rates, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of combining expanded NK cells with radiotherapy and targeted therapy for HNSCC.
- To evaluate the potential of cetuximab and anti-PD-1 antibodies in enhancing NK cell-mediated anti-tumor activity in HNSCC models.
Main Methods:
- NK cells were isolated, activated, and expanded from healthy donors.
- HNSCC cell lines (FaDu, SCC-47) were xenografted into NOD/SCID mice.
- Mice received a combination of radiotherapy, cetuximab, and/or anti-PD-1 antibodies, followed by adoptive transfer of expanded NK cells.
Main Results:
- Radiotherapy enhanced NK cell-mediated tumor cell killing by increasing activating ligands.
- The combination of cetuximab, radiotherapy, and NK cells significantly suppressed tumor progression and improved survival rates.
- The addition of anti-PD-1 antibodies did not yield additional therapeutic benefits in this HNSCC model.
Conclusions:
- A multimodal treatment strategy incorporating cetuximab, radiotherapy, and NK cells demonstrates significant therapeutic potential for HNSCC.
- This combination therapy represents a novel and promising approach to improve treatment efficacy for head and neck cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...